Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Virax Biolabs Group Ltd. Class A ( (VRAX) ) has shared an announcement.
On December 2, 2025, Virax Biolabs Group Ltd. released its unaudited interim financial statements for the period ending September 30, 2025. The report highlights a decrease in total assets and an increase in net loss compared to the previous year, reflecting ongoing challenges in the company’s financial performance.
The most recent analyst rating on (VRAX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Ltd. operates in the biotechnology industry, focusing on the development and commercialization of diagnostic test kits and other related products.
Average Trading Volume: 242,833
Technical Sentiment Signal: Sell
Current Market Cap: $1.7M
Find detailed analytics on VRAX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Supporting the Responsible Growth of our Industry…” Boeing Stock (NYSE:BA) Notches Up With Carbon Purchase
- “Secure Foundations for the Era of Frontier AI”: Microsoft Stock (NASDAQ:MSFT) Gains With New AI Plans
- Elon Musk Made $158 Billion in 2025, But Received None of It. Tesla Stock (NASDAQ:TSLA) Surges